网站大量收购独家精品文档,联系QQ:2885784924

系统性红斑狼疮诊治进展.pptVIP

  1. 1、本文档共65页,可阅读全部内容。
  2. 2、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
  3. 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载
  4. 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
  5. 5、该文档为VIP文档,如果想要下载,成为VIP会员后,下载免费。
  6. 6、成为VIP后,下载本文档将扣除1次下载权益。下载后,不支持退款、换文档。如有疑问请联系我们
  7. 7、成为VIP后,您将拥有八大权益,权益包括:VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
  8. 8、VIP文档为合作方或网友上传,每下载1次, 网站将根据用户上传文档的质量评分、类型等,对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档
查看更多
艾拉莫德可改善MRL/lpr免疫性肾炎。雌性MRL/lpr小鼠,自第8周龄起给予艾拉莫德 30mg/kg·d(n=14)或空白载体溶液(n=16)。 (A) 小鼠蛋白尿水平。 (B) 第28周处死所有小鼠观察肾脏病理。艾拉莫德治疗后小鼠肾组织,大致正常;安慰剂组小鼠肾脏,可见新月体、小球硬化(星号)、间质炎症细胞浸润及管型等多种病变。 (C)小鼠肾脏病理评分 (D)MRL/lpr小鼠,自第8周龄起给予艾拉莫德30mg/kg·d或空白载体溶液。艾拉莫德可降低小鼠血清抗dsDNA抗体滴度。 (E)艾拉莫德在给药12w后可显著降低MRL/lpr小鼠血清各亚型免疫球蛋白水平,与阳性对照药物环磷酰胺(Cyc)作用接近。 ? * Abstract Objective To assess the efficacy and safety of subcutaneous (SC) belimumab in patients with systemic lupus erythematosus (SLE). Methods Patients with moderate-to-severe SLE (SELENA-SLEDAI ≥8) were randomized (2:1) to weekly belimumab 200 mg SC or placebo by prefilled syringe, plus standard SLE therapy (SoC), for 52 weeks. Primary endpoint was SLE Responder Index (SRI4) at Week 52. Secondary endpoints were time to severe flare and reduction in corticosteroid dose. Safety was assessed by adverse event (AE) reporting and laboratory testing. Results Of 839 patients randomized, 836 (556 belimumab/280 placebo) received treatment; 159 withdrew. At entry, mean SELENA-SLEDAI scores were 10.5 (belimumab) and 10.3 (placebo). More patients who received belimumab were SRI4 responders than those who received placebo (61.4% vs 48.4%; odds ratio [OR] [95% CI]: 1.68 [1.25, 2.25]; p=0.0006). In the belimumab group, time to and risk of severe flare were improved (median 171.0 versus 118.0 days; HR [95% CI]: 0.51 [0.35, 0.74]; p=0.0004), and more patients reduced corticosteroid dose by ≥25% to ≤7.5 mg/day during Weeks 40-52 (18.2% vs 11.9%; OR [95% CI]: 1.65 [0.95, 2.84]; p=0.0732), compared with placebo. AE incidence was comparable between treatment groups; serious AEs were reported for 10.8% (belimumab) and 15.7% (placebo) of patients. Hypoglobulinemia immunoglobulin G worsening by ≥2 grades occurred in 0.9% (belimumab) and 1.4% (placebo) of patients. Conclusion In patients with moderate-to-severe SLE, weekly belimumab 200 mg SC plus SoC significantly improved SRI4 response, decreased severe flare compared with placebo, and had a safety profile similar t

文档评论(0)

celkhn0210 + 关注
实名认证
文档贡献者

该用户很懒,什么也没介绍

1亿VIP精品文档

相关文档